Form 4: Novavax CSO O'Hara Vests RSUs, Boosts Stake

Novavax's Chief Strategy Officer, Elaine O'Hara, acquired common stock through RSU vesting and sold shares for tax obligations, increasing her direct beneficial ownership.

Summary

• Elaine O'Hara, EVP, Chief Strategy Officer of Novavax Inc. (NVAX), reported transactions on March 3, 2026.
• Acquired 56,334 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Disposed of 22,429 shares of common stock at a price of $9.49 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, O'Hara directly beneficially owns 134,642 shares of Novavax common stock.
• 112,666 Restricted Stock Units remain beneficially owned, with future vesting scheduled.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting a routine compensation event where a key executive continues to build equity in the company, albeit with a portion sold for tax purposes.

Positives

• Executive Elaine O'Hara continues to hold a significant number of shares (134,642 common shares and 112,666 RSUs), indicating ongoing alignment with shareholder interests.
• The vesting of RSUs demonstrates continued employment and commitment of a key executive.

Negatives

• A portion of the vested shares (22,429 shares) was sold to cover tax liabilities, reducing the net increase in direct ownership.

Future Outlook

One-third of the remaining 112,666 Restricted Stock Units are scheduled to vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common in the biotechnology and pharmaceutical sectors. These events typically reflect pre-scheduled compensation plans rather than discretionary trading, and often signal an executive's continued tenure and alignment with company performance.

Comparison to Industry Standards

• Executive compensation structures in the biotechnology industry frequently include Restricted Stock Units (RSUs) to incentivize long-term performance and retention.
• The vesting schedule of one-third annually over three years is a standard practice, comparable to similar plans at companies like Moderna (MRNA) or BioNTech (BNTX), where executive equity compensation is tied to multi-year service periods.

Stakeholder Impact

• Shareholders: Indicates continued commitment and alignment of a key executive with the company's long-term performance.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of the remaining 112,666 Restricted Stock Units on the first three anniversaries of March 3, 2025, subject to continued employment.

Key Dates

Keywords

NVAX, Novavax, Form 4, insider trading, RSU, stock vesting, executive compensation